Drug-drug interactions with immunosuppressive agents: Review of the in vitro functional assays and role of cytochrome P450 enzymes

Transplantation

Volumn 85, Issue 9, 2008, Pages 1222-1229

  Elbarbry, Fawzy A ^a   Marfleet, Travis ^a   Shoker, Ahmed S ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

Cytochrome P450 enzymes; Drug interactions; Immunosuppressive drugs

Indexed keywords

ALPHA NAPHTHOFLAVONE; CALCINEURIN INHIBITOR; CARBAMAZEPINE; CLOPIDOGREL; CYCLOSPORIN A; CYTOCHROME P450; ERYTHROMYCIN; GESTODENE; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PILOCARPINE; QUINIDINE; RAPAMYCIN; RECOMBINANT ENZYME; RIFAMPICIN; SERTRALINE; SULFAPHENAZOLE; TACROLIMUS; TICLOPIDINE; TROLEANDOMYCIN; TRYPTAMINE; UNINDEXED DRUG;

ANTIBODY SPECIFICITY; CORRELATION ANALYSIS; DRUG INHIBITION; DRUG INTERACTION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ASSAY; FOOD DRUG INTERACTION; GRAFT REJECTION; GRAPEFRUIT JUICE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY INJURY; MOLECULAR PROBE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ADULT; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOENZYMES; LIVER; SAFETY; TRANSPLANTATION IMMUNOLOGY;

EID: 43449088532     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816fc03b     Document Type: Review

References (48)

1. Guengerich FP. In: Ortiz de Montellano PR, ed. Cytochrome P450: Structure, mechanism, and biochemistry. New York, Kluwer Academic/ Plenum 2005, pp 377-475.
2. Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant 2005; 5: 207.
3. Seifeldin R. Drug interactions in transplantation. Clin Ther 1995; 17: 1043.
4. Kelly P, Kahan BD. Review: Metabolism of immunosuppressant drugs. Curr Drug Metab 2002; 3: 275.
5. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 472.
6. Krensky AM, Vincenti F, Bennett WM. Immunomodulators. In: Laurence LB, John SL, Keith LP, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York, McGraw-Hill 2007, pp 1405-1432.
7. Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol Rev 1988; 40: 243.
8. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: Phase I oxidative enzymes. J Pharmacol Exp Ther 2002; 300: 355.
9. Shimada T, Yamazaki H, Mimura M, et al. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab Dispos 1996; 24: 515.
10. Blake MJ, Castro L, Leeder JS, et al. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med 2005; 10: 123.
11. Hakkola J, Tanaka E, Pelkonen O. Developmental expression of cytochrome P450 enzymes in human liver. Pharmacol Toxicol 1998; 82: 209.
12. Treluyer JM, Jacqz-Aigrain E, Alvarez F, et al. Expression of CYP2D6 in developing human liver. Eur J Biochem 1991; 202: 583.
13. Alvan G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533.
14. Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev 2004; 36: 511.
15. Elbarbry FA, McNamara PJ, Alcorn J. Ontogeny of hepatic CYP1A2 and CYP2E1 expression in rat. J Biochem Mol Toxicol 2007; 21: 41.
16. Kivisto KT, Bookjans G, Fromm MF, et al. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996; 42: 387.
17. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773.
18. Lee JI, Chaves-Gnecco D, Amico JA, et al. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 2002; 72: 718.
19. Picard N, Cresteil T, Premaud A, et al. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004; 26: 600.
20. Niwa T, Yamamoto S, Saito M, et al. Effect of cyclosporine and tacrolimus on cytochrome p450 activities in human liver microsomes. Yakugaku Zasshi 2007; 127: 209.
21. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 753.
22. Vincent SH, Karanam BV, Painter SK, et al. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: Identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 1992; 294: 454.
23. Christians U, Sewing KF. Cyclosporin metabolism in transplant patients. Pharmacol Ther 1993; 57: 291.
24. Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871.
25. Lemahieu WP, Maes BD, Verbeke K, et al. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: Consequences for FK506 assimilation. Kidney Int 2005; 67: 1152.
26. Bai S, Brunner LJ, Stepkowski SM, et al. Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat1. Transplantation 2001; 71: 1585.
27. Frassetto L, Thai T, Aggarwal AM, et al. Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+- subjects. Drug Metab Pharmacokinet 2003; 18: 114.
28. Gerntholtz T, Pascoe MD, Botha JF, et al. The use of a cyclosporin-ketoconazole combination: Making renal transplantation affordable in developing countries. Eur J Clin Pharmacol 2004; 60: 143.
29. Rendic S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab Rev 2002; 34: 83.
30. Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007; 81: 228.
31. Eng HS, Mohamed Z, Calne R, et al. The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int 2006; 69: 1858.
32. Chowbay B, Cumaraswamy S, Cheung YB, et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13: 89.
33. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4: 914.
34. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383.
35. Haufroid V, Mourad M, Van KV, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147.
36. Bonhomme-Faivre L, Devocelle A, Saliba F, et al. MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation 2004; 78: 21.
37. Fredericks S, Jorga A, MacPhee IA, et al. Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clin Transplant 2007; 21: 252.
38. Thervet E, Legendre C, Beaune P, et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005; 6: 37.
39. Thummel KE. A genetic test for immunosuppressant dose selection? Pharmacogenetics 2004; 14: 145.
40. Christians U, Braun F, Sattler M, et al. Interactions of FK 506 and cyclosporine metabolism. Transplant Proc 1991; 23: 2794.
41. Le MY, Djebli N, Szelag JC, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006; 80: 51.
42. Sadaba B, Campanero MA, Quetglas EG, et al. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004; 36: 3226.
43. Ghobrial RR, Hamashima T, Wang ME, et al. Induction of transplantation tolerance by chimeric donor/recipient class I RT1.Aa molecules. Transplantation 1996; 62: 1002.
44. Napoli KL, Wang ME, Stepkowski SM, et al. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: Evidence for pharmacokinetic interactions. Ther Drug Monit 1998; 20: 123.
45. Browska-Zamojcin E, Pawlik A, Domanski L, et al. Cyclosporine and sirolimus interaction in a kidney transplant patient. Transplant Proc 2005; 37: 2317.
46. Kaplan B, Meier-Kriesche HU, Napoli KL, et al. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998; 63: 48.
47. Elbarbry FA, Shoker A. Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients. Clin Biochem 2007; 40: 752.
48. Shipkova M, Armstrong VW, Wieland E, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999; 126: 1075.